DVA Earnings

DVA reported its FY2025Q4 earnings on 2026-02-02, showcasing a revenue of 0.00 against an estimate of 4.00B, resulting in a 0% surprise. The EPS was 0, surpassing the expected 3.24 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following DVA's FY2025Q4 earnings announcement on 2026-02-02, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, DVA's stock price tends to shift by an average of -0.83% in the 10 days leading up to earnings and +1.38% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate DVA’s annual revenue to reach 4.00B, while the EPS is projected at 3.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.53% and EPS estimates Revise Upward by 0.42% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between DVA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.53%, while EPS estimates moved Revise Upward by 0.42% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, DVA's stock price typically moves by -0.83% in the 10 days before its earnings and +1.38% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 3.00 and revenue of 4.00B.

The earnings call reveals several negative indicators: a decline in treatment volume, increased patient care costs, and a significant operating income shortfall. The reaffirmed EPS guidance is overshadowed by weak guidance on treatment volumes and RPT growth. The Q&A session highlights concerns over mortality rates, unpredictable IKC revenue timing, and the impact of a cyber incident. Despite some positive aspects like technology investments and debt management, the overall sentiment is negative, particularly with the lack of clear guidance and the market's reaction to these uncertainties.